Search research articles
Contact Us
Filters
Showing results (1-10 of 32) with videos related to
Page
of 4
Sort By:
Therapeutic Innovation & Regulatory Science
|
June 13, 2023
AI/ML in Precision Medicine: A Look Beyond the Hype
Zhiheng Xu, Bipasa Biswas, Lin Li, et al.
Archives of Toxicology
|
October 10, 2018
The Yin-Yang of CYP3A4: a Bayesian meta-analysis to quantify inhibition and induction of CYP3A4 metabolism in humans and refine uncertainty factors for mixture risk assessment
Nadia Quignot, Witold Wiecek, Billy Amzal, et al.
Plos One
|
September 9, 2017
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma
Billy Amzal, Shuai Fu, Jie Meng, et al.
BMC Biotechnology
|
February 18, 2011
A statistical assessment of differences and equivalences between genetically modified and reference plant varieties
Hilko van der Voet, Joe N Perry, Billy Amzal, et al.
Toxicology Letters
|
November 24, 2020
Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment
Nadia Quignot, Witold Więcek, Leonie Lautz, et al.
Environmental Health : a Global Access Science Source
|
December 20, 2011
Relation between dietary cadmium intake and biomarkers of cadmium exposure in premenopausal women accounting for body iron stores
Bettina Julin, Marie Vahter, Billy Amzal, et al.
Environmental Health Perspectives
|
August 13, 2009
Population toxicokinetic modeling of cadmium for health risk assessment
Billy Amzal, Bettina Julin, Marie Vahter, et al.
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
Pragmatic Multicriteria Decision Analysis (MCDA) Combined With Advanced Pharmacoepidemiology for Benefit-Risk Assessments of Medicines Adapted to the Real-Life Constraints of Regulators: Development and Case Study
Mireille M Goetghebeur, Monika Wagner, Mateusz Nikodem, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
September 26, 2012
Population effects and variability
Jean Lou Dorne, Billy Amzal, Frédéric Bois, et al.
Clinical Pharmacokinetics
|
January 5, 2007
Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates
Sandrine Micallef, Billy Amzal, Véronique Bach, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 32) with videos related to
Sort By:
Page
of 4
Therapeutic Innovation & Regulatory Science
|
June 13, 2023
AI/ML in Precision Medicine: A Look Beyond the Hype
Zhiheng Xu, Bipasa Biswas, Lin Li, et al.
Archives of Toxicology
|
October 10, 2018
The Yin-Yang of CYP3A4: a Bayesian meta-analysis to quantify inhibition and induction of CYP3A4 metabolism in humans and refine uncertainty factors for mixture risk assessment
Nadia Quignot, Witold Wiecek, Billy Amzal, et al.
Plos One
|
September 9, 2017
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma
Billy Amzal, Shuai Fu, Jie Meng, et al.
BMC Biotechnology
|
February 18, 2011
A statistical assessment of differences and equivalences between genetically modified and reference plant varieties
Hilko van der Voet, Joe N Perry, Billy Amzal, et al.
Toxicology Letters
|
November 24, 2020
Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment
Nadia Quignot, Witold Więcek, Leonie Lautz, et al.
Environmental Health : a Global Access Science Source
|
December 20, 2011
Relation between dietary cadmium intake and biomarkers of cadmium exposure in premenopausal women accounting for body iron stores
Bettina Julin, Marie Vahter, Billy Amzal, et al.
Environmental Health Perspectives
|
August 13, 2009
Population toxicokinetic modeling of cadmium for health risk assessment
Billy Amzal, Bettina Julin, Marie Vahter, et al.
Therapeutic Innovation & Regulatory Science
|
September 21, 2018
Pragmatic Multicriteria Decision Analysis (MCDA) Combined With Advanced Pharmacoepidemiology for Benefit-Risk Assessments of Medicines Adapted to the Real-Life Constraints of Regulators: Development and Case Study
Mireille M Goetghebeur, Monika Wagner, Mateusz Nikodem, et al.
Methods in Molecular Biology (Clifton, N.J.)
|
September 26, 2012
Population effects and variability
Jean Lou Dorne, Billy Amzal, Frédéric Bois, et al.
Clinical Pharmacokinetics
|
January 5, 2007
Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates
Sandrine Micallef, Billy Amzal, Véronique Bach, et al.
Page
of 4